Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. It discovers and develops precision medicines for oncology and inflammatory disease using its proprietary AP3 (Acrivon Predictive Precision Proteomics) platform, which applies generative artificial intelligence (AI) to phosphoproteomic data to predict patient responses and design differentiated drug candidates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Because ACRV is a single operating company rather than a fund, it carries no expense ratio, holds no diversified basket of securities, and has no sector allocation in the traditional fund sense. Its entire equity value is concentrated in one biotechnology business, whose revenue is effectively nil while it advances a clinical pipeline. Lead programs include ACR-368 (prexasertib), a CHK1/CHK2 inhibitor in a registrational-intent Phase 2b trial for serous endometrial cancer; ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor; ACR-7280, an oral CDK11 inhibitor in IND-enabling studies; and ACR-525, a Phase 2-ready JAK1 inhibitor acquired in November 2026 to build an immunology and inflammation franchise. This concentration makes the stock highly sensitive to single clinical readouts and financing events.
Over the past 30 days, ACRV fell from a closing price of $1.83 on October 21 to about $1.18, a decline of approximately 36%. The move was not a single-gap event but a gradual, volatile slide punctuated by sharp down days, most recently in mid-November. Over the latest quarter, the decline has been steeper: from roughly $2.20 in late August to about $1.18, a drop of approximately 47%. The trend has been consistently downward rather than range-bound, reflecting persistent selling pressure in a low-liquidity micro-cap name.
Several company-specific developments shaped the recent decline. Acrivon reported Q3 2026 results in mid-November, posting a net loss of $17.9 million, or $0.42 per share (EPS), on research and development spending of $14.5 million. While results modestly exceeded consensus loss estimates, the pre-revenue profile left little fundamental support for the share price.
In early November, the company expanded into immunology by acquiring ACR-525 and a preclinical PKCθ inhibitor program, a strategically positive but cash-consuming step that broadened the pipeline without adding near-term revenue. The period also featured the ACR-2316 dose-escalation presentation at a late-breaking oncology session on November 20, an event that often triggers repositioning in small-cap biotech as investors weigh efficacy and safety data. Combined with thin trading volumes and an earlier 1-for-15 reverse stock split (effective April 2026) executed to maintain Nasdaq's minimum bid-price compliance, these factors contributed to elevated volatility and a downward bias.
The three-month slide reflects broader structural pressures rather than a single catalyst. Micro-cap and clinical-stage biotechnology names have faced a challenging environment as investors favor revenue-generating and later-stage assets over pre-commercial platforms. Acrivon's ongoing cash burn, absence of product revenue, and dependence on future financings have weighed on sentiment even though its $77.8 million cash balance funds operations into Q4 2027.
Pipeline progress has been genuine but preclinical or early-stage: ACR-7280 demonstrated complete tumor regression in aggressive AML (acute myeloid leukemia) xenograft models, and ACR-2316 showed durable clinical activity in heavily pretreated patients. Yet these data points have not yet translated into sustained equity re-rating. The quarter's decline, therefore, reflects a combination of sector rotation away from speculative biotech, investor impatience with early-stage timelines, and concentration risk inherent to a single-program-driven micro-cap.
The near-term outlook hinges primarily on clinical execution and capital strategy. The prespecified interim analysis of the ACR-368 Phase 2b trial in all-comer serous endometrial cancer is expected in Q4 2026 and represents the most significant potential value inflection. Expansion-phase updates for ACR-2316, the planned IND (Investigational New Drug) filing for ACR-7280 in the first half of 2027, and FDA alignment on the ACR-525 eosinophilic esophagitis trial design are additional milestones.
Investors should also monitor cash runway and any future financing activity, which can dilute existing shareholders in pre-revenue biotechs, as well as Nasdaq listing compliance. Macroeconomic factors such as interest-rate expectations and risk appetite for speculative healthcare names will continue to influence micro-cap valuations. As with all clinical-stage companies, binary trial outcomes and regulatory decisions remain the dominant risks.
I often turn to Tickeron’s AI-powered platforms when analyzing names like ACRV. The AI Screener lets me quickly filter for similar micro-cap biotechs based on volatility, technical signals, and fundamentals, which helps put single-stock moves into broader context without spending hours on manual charts. It has become a regular part of how I cross-check ideas before digging deeper into company-specific catalysts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
ACRV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 35 instances where the indicator turned negative. In 32 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRV as a result. In 65 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRV's RSI Indicator exited the oversold zone, 28 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.596). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology